Europe
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.
New service reduces the risk, expenditure and time required for the later stages of antibody development
Peregrine Ventures, a leading Israeli med-tech venture capital fund, just closed its fourth fund, Peregrine 4, raising $115 million.
Only 28 per cent of people believe cancers can be controlled long term – yet the average patient now lives more than 10 years from diagnosis
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids.
BC Platforms announced that it has formed a partnership with Life &Brain Genomics, a division of Life & Brain GmbH.
Blood tests to be used to read entire genetic code of people attending a GP surgery, to look for faulty genes relating to cancer and heart disease
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older.
PRESS RELEASES